Skip to main content
Top
Published in: Inflammation 3/2012

Open Access 01-06-2012

The Association Between Self-Reported Symptoms of Recent Airway Infection and CRP Values in a General Population

The Tromsø Study: Tromsø 6

Authors: Hasse Melbye, Kristine Amundsen, Jan Brox, Anne-Elise Eggen

Published in: Inflammation | Issue 3/2012

Login to get access

Abstract

C-reactive protein (CRP) is a much used biomarker for respiratory tract infection; however, the influence of airway infection on the CRP level in the general population has not been well described. The study aimed to evaluate the impact of recent symptoms of airway infection on the CRP level and how the predictive power of other known CRP predictors is influenced by taking respiratory symptoms into account. A total of 6,325 participants, aged 38–87 years, in the Tromsø Study, a repeated population-based survey, were examined with questionnaires, measurements of height and weight, spirometry, and high-sensitivity CRP analyses. The mean CRP value was 2.86 mg/L, and the geometric mean was 1.51 mg/L. Geometric means above 2.0 mg/L were found in the subgroups with the following characteristics: self-reported COPD, diabetes, recent symptoms of airway infection, forced expiratory volume in 1 s (FEV1) <80% predicted, body mass index (BMI) ≥30, and subjects treated with inhaled or oral corticosteroids. Among the subjects who reported recent airway infection, 10.5% had a CRP value of ≥10 mg/L, compared to 3.3% among the remaining participants. By multivariate analysis, BMI was the strongest independent predictor of the CRP level, followed by recent airway infection, FEV1% predicted, age, and current smoking. The study clearly demonstrates that a report of recent symptoms of airway infection strongly predicts the CRP level in the population. Such symptoms were shared rather equally between subgroups with increased CRP level, and the risk of being an important confounder in epidemiological studies is probably low. In the clinical setting, care should be taken when using the CRP level as a guide for medical prevention of chronic diseases.
Literature
1.
go back to reference Black, S., I. Kushner, and D. Samols. 2004. C-reactive protein. Journal of Biological Chemistry 279(47): 48487–48490.PubMedCrossRef Black, S., I. Kushner, and D. Samols. 2004. C-reactive protein. Journal of Biological Chemistry 279(47): 48487–48490.PubMedCrossRef
2.
go back to reference Hansson, L.O., J.U. Hedlund, and A.B. Ortqvist. 1997. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scandinavian Journal of Clinical and Laboratory Investigation 57(2): 111–118.PubMedCrossRef Hansson, L.O., J.U. Hedlund, and A.B. Ortqvist. 1997. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scandinavian Journal of Clinical and Laboratory Investigation 57(2): 111–118.PubMedCrossRef
3.
go back to reference Smith, R.P., B.J. Lipworth, I.A. Cree, E.M. Spiers, and J.H. Winter. 1995. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 108(5): 1288–1291.PubMedCrossRef Smith, R.P., B.J. Lipworth, I.A. Cree, E.M. Spiers, and J.H. Winter. 1995. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 108(5): 1288–1291.PubMedCrossRef
4.
go back to reference Povoa, P., L. Coelho, E. Almeida, A. Fernandes, R. Mealha, P. Moreira, et al. 2005. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. European Respiratory Journal 25(5): 804–812.PubMedCrossRef Povoa, P., L. Coelho, E. Almeida, A. Fernandes, R. Mealha, P. Moreira, et al. 2005. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. European Respiratory Journal 25(5): 804–812.PubMedCrossRef
5.
go back to reference Melbye, H., B. Straume, and J. Brox. 1992. Laboratory tests for pneumonia in general practice: the diagnostic values depend on the duration of illness. Scandinavian Journal of Primary Health Care 10(3): 234–240.PubMedCrossRef Melbye, H., B. Straume, and J. Brox. 1992. Laboratory tests for pneumonia in general practice: the diagnostic values depend on the duration of illness. Scandinavian Journal of Primary Health Care 10(3): 234–240.PubMedCrossRef
6.
go back to reference Hopstaken, R.M., J.W. Muris, J.A. Knottnerus, A.D. Kester, P.E. Rinkens, and G.J. Dinant. 2003. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. British Journal of General Practice 53(490): 358–364.PubMed Hopstaken, R.M., J.W. Muris, J.A. Knottnerus, A.D. Kester, P.E. Rinkens, and G.J. Dinant. 2003. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. British Journal of General Practice 53(490): 358–364.PubMed
7.
go back to reference Ruuskanen, O., A. Putto, H. Sarkkinen, O. Meurman, and K. Irjala. 1985. C-reactive protein in respiratory virus infections. Journal of Pediatrics 107(1): 97–100.PubMedCrossRef Ruuskanen, O., A. Putto, H. Sarkkinen, O. Meurman, and K. Irjala. 1985. C-reactive protein in respiratory virus infections. Journal of Pediatrics 107(1): 97–100.PubMedCrossRef
8.
go back to reference Melbye, H., D. Hvidsten, A. Holm, S.A. Nordbo, and J. Brox. 2004. The course of C-reactive protein response in untreated upper respiratory tract infection. British Journal of General Practice 54(506): 653–658.PubMed Melbye, H., D. Hvidsten, A. Holm, S.A. Nordbo, and J. Brox. 2004. The course of C-reactive protein response in untreated upper respiratory tract infection. British Journal of General Practice 54(506): 653–658.PubMed
9.
go back to reference Pepys, M.B., and G.M. Hirschfield. 2003. C-reactive protein: a critical update. The Journal of Clinical Investigation 111(12): 1805–1812.PubMed Pepys, M.B., and G.M. Hirschfield. 2003. C-reactive protein: a critical update. The Journal of Clinical Investigation 111(12): 1805–1812.PubMed
10.
go back to reference Casas, J.P., T. Shah, A.D. Hingorani, J. Danesh, and M.B. Pepys. 2008. C-reactive protein and coronary heart disease: a critical review. Journal of Internal Medicine 264(4): 295–314.PubMedCrossRef Casas, J.P., T. Shah, A.D. Hingorani, J. Danesh, and M.B. Pepys. 2008. C-reactive protein and coronary heart disease: a critical review. Journal of Internal Medicine 264(4): 295–314.PubMedCrossRef
11.
go back to reference Lee, J.S., O.Y. Kwon, H.S. Choi, H.P. Hong, and Y.G. Ko. 2011. Serum C-reactive protein level is a predictive factor for 14-day mortality of patients with advanced cancer who present to the emergency department with acute symptoms. Academic Emergency Medicine 18(4): 440–442.PubMedCrossRef Lee, J.S., O.Y. Kwon, H.S. Choi, H.P. Hong, and Y.G. Ko. 2011. Serum C-reactive protein level is a predictive factor for 14-day mortality of patients with advanced cancer who present to the emergency department with acute symptoms. Academic Emergency Medicine 18(4): 440–442.PubMedCrossRef
12.
go back to reference Marsik, C., L. Kazemi-Shirazi, T. Schickbauer, S. Winkler, C. Joukhadar, O.F. Wagner, et al. 2008. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clinical Chemistry 54(2): 343–349.PubMedCrossRef Marsik, C., L. Kazemi-Shirazi, T. Schickbauer, S. Winkler, C. Joukhadar, O.F. Wagner, et al. 2008. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clinical Chemistry 54(2): 343–349.PubMedCrossRef
13.
go back to reference Ridker, P.M., J. MacFadyen, P. Libby, and R.J. Glynn. 2010. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). The American Journal of Cardiology 106(2): 204–209.PubMedCrossRef Ridker, P.M., J. MacFadyen, P. Libby, and R.J. Glynn. 2010. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). The American Journal of Cardiology 106(2): 204–209.PubMedCrossRef
14.
go back to reference Pinto-Plata, V.M., H. Mullerova, J.F. Toso, M. Feudjo-Tepie, J.B. Soriano, R.S. Vessey, et al. 2006. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61(1): 23–28.PubMedCrossRef Pinto-Plata, V.M., H. Mullerova, J.F. Toso, M. Feudjo-Tepie, J.B. Soriano, R.S. Vessey, et al. 2006. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61(1): 23–28.PubMedCrossRef
15.
go back to reference Sin, D.D., P. Lacy, E. York, and S.F. Man. 2004. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 170(7): 760–765.PubMedCrossRef Sin, D.D., P. Lacy, E. York, and S.F. Man. 2004. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 170(7): 760–765.PubMedCrossRef
16.
go back to reference Eilertsen, A.L., E. Hoibraaten, I. Os, T.O. Andersen, L. Sandvik, and P.M. Sandset. 2005. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 52(2): 111–118.PubMedCrossRef Eilertsen, A.L., E. Hoibraaten, I. Os, T.O. Andersen, L. Sandvik, and P.M. Sandset. 2005. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 52(2): 111–118.PubMedCrossRef
17.
go back to reference Imhof, A., M. Frohlich, H. Loewel, N. Helbecque, M. Woodward, P. Amouyel, et al. 2003. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clinical Chemistry 49(4): 669–672.PubMedCrossRef Imhof, A., M. Frohlich, H. Loewel, N. Helbecque, M. Woodward, P. Amouyel, et al. 2003. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clinical Chemistry 49(4): 669–672.PubMedCrossRef
18.
go back to reference Hutchinson, W.L., W. Koenig, M. Frohlich, M. Sund, G.D. Lowe, and M.B. Pepys. 2000. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clinical Chemistry 46(7): 934–938.PubMed Hutchinson, W.L., W. Koenig, M. Frohlich, M. Sund, G.D. Lowe, and M.B. Pepys. 2000. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clinical Chemistry 46(7): 934–938.PubMed
19.
go back to reference Tracy, R.P., B.M. Psaty, E. Macy, E.G. Bovill, M. Cushman, E.S. Cornell, et al. 1997. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arteriosclerosis, Thrombosis, and Vascular Biology 17(10): 2167–2176.PubMedCrossRef Tracy, R.P., B.M. Psaty, E. Macy, E.G. Bovill, M. Cushman, E.S. Cornell, et al. 1997. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arteriosclerosis, Thrombosis, and Vascular Biology 17(10): 2167–2176.PubMedCrossRef
20.
go back to reference Melbye, H., D.S. Halvorsen, I. Hartz, A. Medbo, J. Brox, A.E. Eggen, et al. 2007. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respiratory Medicine 101(12): 2541–2549.PubMedCrossRef Melbye, H., D.S. Halvorsen, I. Hartz, A. Medbo, J. Brox, A.E. Eggen, et al. 2007. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respiratory Medicine 101(12): 2541–2549.PubMedCrossRef
21.
go back to reference Khera, A., G.L. Vega, S.R. Das, C. Ayers, D.K. McGuire, S.M. Grundy, et al. 2009. Sex differences in the relationship between C-reactive protein and body fat. Journal of Clinical Endocrinology and Metabolism 94(9): 3251–3258.PubMedCrossRef Khera, A., G.L. Vega, S.R. Das, C. Ayers, D.K. McGuire, S.M. Grundy, et al. 2009. Sex differences in the relationship between C-reactive protein and body fat. Journal of Clinical Endocrinology and Metabolism 94(9): 3251–3258.PubMedCrossRef
22.
go back to reference Ridker, P.M., R.J. Glynn, and C.H. Hennekens. 1998. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97(20): 2007–2011.PubMed Ridker, P.M., R.J. Glynn, and C.H. Hennekens. 1998. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97(20): 2007–2011.PubMed
23.
go back to reference Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 286(3): 327–334.PubMedCrossRef Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 286(3): 327–334.PubMedCrossRef
24.
go back to reference Khera, A., D.K. McGuire, S.A. Murphy, H.G. Stanek, S.R. Das, W. Vongpatanasin, et al. 2005. Race and gender differences in C-reactive protein levels. Journal of the American College of Cardiology 46(3): 464–469.PubMedCrossRef Khera, A., D.K. McGuire, S.A. Murphy, H.G. Stanek, S.R. Das, W. Vongpatanasin, et al. 2005. Race and gender differences in C-reactive protein levels. Journal of the American College of Cardiology 46(3): 464–469.PubMedCrossRef
25.
go back to reference Mannino, D.M., E.S. Ford, and S.C. Redd. 2003. Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination. American Journal of Medicine 114(9): 758–762.PubMedCrossRef Mannino, D.M., E.S. Ford, and S.C. Redd. 2003. Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination. American Journal of Medicine 114(9): 758–762.PubMedCrossRef
26.
go back to reference Jacobsen, B.K., A.E. Eggen, E.B. Mathiesen, T. Wilsgaard, and I. Njolstad. 2011. Cohort profile: The Tromso Study. International Journal of Epidemiology. doi:10.1093/ije/dyr049. Jacobsen, B.K., A.E. Eggen, E.B. Mathiesen, T. Wilsgaard, and I. Njolstad. 2011. Cohort profile: The Tromso Study. International Journal of Epidemiology. doi:10.​1093/​ije/​dyr049.
27.
go back to reference 1995. Standardization of Spirometry,1994 Update. American Thoracic Society. American Journal of Respiratory and Critical Care Medicine 152(3):1107–1136. 1995. Standardization of Spirometry,1994 Update. American Thoracic Society. American Journal of Respiratory and Critical Care Medicine 152(3):1107–1136.
28.
go back to reference Langhammer, A., R. Johnsen, A. Gulsvik, T.L. Holmen, and L. Bjermer. 2001. Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trondelag study. European Respiratory Journal 18(5): 770–779.PubMedCrossRef Langhammer, A., R. Johnsen, A. Gulsvik, T.L. Holmen, and L. Bjermer. 2001. Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trondelag study. European Respiratory Journal 18(5): 770–779.PubMedCrossRef
Metadata
Title
The Association Between Self-Reported Symptoms of Recent Airway Infection and CRP Values in a General Population
The Tromsø Study: Tromsø 6
Authors
Hasse Melbye
Kristine Amundsen
Jan Brox
Anne-Elise Eggen
Publication date
01-06-2012
Publisher
Springer US
Published in
Inflammation / Issue 3/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9405-6

Other articles of this Issue 3/2012

Inflammation 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine